Ray Dalio’s Amicus Therapeutics FOLD Stock Holding History

Ray Dalio’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-32,274	Closed	-$460K	–	1091
2025 Q4	$460K	Buy	+32,274	New	+$317K	﹤0.01%	980

Other funds holding FOLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Ray Dalio's FOLD Position: Q1 2026 in Review

Ray Dalio sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 32,274 shares — an estimated $460K sold.

Ray Dalio first reported a position in FOLD in Q4 2025 and held it in 1 quarter. The position peaked at $460K in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Ray Dalio reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Ray Dalio sold 32,274 Amicus Therapeutics shares in Q1 2026, an estimated $460K.
Ray Dalio first reported a position in Amicus Therapeutics in Q4 2025 and held it in 1 quarter.
Ray Dalio's Amicus Therapeutics position peaked at $460K in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.